Company intelligence / Profile preview
Gene Signal International SA
Lausanne, Vaud, Switzerlandorpha.net ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Gene Signal developed a pipeline focused on modulating angiogenesis using antisense oligonucleotides, proteins, and monoclonal antibodies. Its lead product, aganirsen (GS‑101), an antisense oligonucleotide eye drop for neovascular-associated corneal graft rejection (NV-CGR), completed or nearly completed Phase III trials by 2013. Additional programs were in Phase II or discovery for other ophthalmic and vascular indications. The company has demonstrated preclinical efficacy in models of retinal neovascular disease and ischemic retinopathy.
- Therapeutic areas
- OphthalmologyOncologyCardiovascularDermatology
- Modalities
- Antisense oligonucleotidesProteinsMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical partnerships publicly disclosed as of last available information. The company expressed intent to seek pharma partners for further development/commercialization.
Beyond the preview
Go deeper on Gene Signal International SA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gene Signal International SA.